TerrAscend (TSNDF) Total Non-Current Liabilities (2020 - 2026)
TerrAscend (TSNDF) posted quarterly Total Non-Current Liabilities of $390.5 million for Q1 2026, up 8.97% year-over-year from $358.3 million in Q1 2025, and up 3.18% quarter-over-quarter from $378.4 million in Q4 2025.
TerrAscend (TSNDF) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
TerrAscend (TSNDF) has reported Total Non-Current Liabilities for 7 consecutive years, with $390.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 8.97% year-over-year to $390.5 million; the TTM figure through Mar 2026 stood at $390.5 million (up 8.97% YoY), while the FY2025 annual figure was $378.4 million, up 11.51% from the prior year.
- Total Non-Current Liabilities improved to $390.5 million in Q1 2026 per TSNDF's latest filing, from $378.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $390.5 million in Q1 2026 and bottomed at $218.8 million in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $319.3 million across 5 years, with a median of $339.4 million in 2024.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities plunged 32.16% — and 2025, when it jumped 59.75%.
- TerrAscend's Total Non-Current Liabilities stood at $242.5 million in 2022, then fell by 9.79% to $218.8 million in 2023, then jumped by 55.12% to $339.4 million in 2024, then increased by 11.51% to $378.4 million in 2025, then rose by 3.18% to $390.5 million in 2026.
- Business Quant data shows TSNDF's Total Non-Current Liabilities at $390.5 million in Q1 2026, $378.4 million in Q4 2025, and $383.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | TerrAscend | 182.53 Mn | 140.41 Mn | 36.25 Mn | 407.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 407.67 Mn |
| Mar 31, 2026 | 390.48 Mn |
| Dec 31, 2025 | 378.43 Mn |
| Sep 30, 2025 | 383.47 Mn |
| Jun 30, 2025 | 361.96 Mn |
| Mar 31, 2025 | 358.34 Mn |
| Dec 31, 2024 | 339.37 Mn |
| Sep 30, 2024 | 371.36 Mn |
| Jun 30, 2024 | 356.64 Mn |
| Mar 31, 2024 | 224.31 Mn |
| Dec 31, 2023 | 218.78 Mn |
| Sep 30, 2023 | 303.50 Mn |
| Jun 30, 2023 | 292.66 Mn |
| Mar 31, 2023 | 246.20 Mn |
| Dec 31, 2022 | 242.51 Mn |
| Sep 30, 2022 | 274.32 Mn |
| Jun 30, 2022 | 323.25 Mn |
| Mar 31, 2022 | 362.90 Mn |
| Dec 31, 2021 | 286.79 Mn |
| Dec 31, 2020 | -132.26 Mn |